6-氯-2-(4-氯苯基)咪唑并[1,2-a]吡啶-3-乙酸 | 82626-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 6-氯-2-(4-氯苯基)咪唑并[1,2-a]吡啶-3-乙酸
• 英文名称: 2-(6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)acetic acid
• 英文别名: 6-Chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridine-3-acetic Acid；2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]acetic acid
• CAS: 82626-74-2
• 化学式: C₁₅H₁₀Cl₂N₂O₂
• 分子量: 321.163
• InChiKey: IMKILIAPBKFUTO-UHFFFAOYSA-N

物化性质

• 溶解度：
  二氯甲烷（微溶）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-氯-2-(4-氯苯基)咪唑并[1,2-a]吡啶-3-乙酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 alpidem
  参考文献：
  名称：

  2-苯基咪唑并[1,2-α]吡啶衍生物的合成及其对中心和外围苯并二氮杂receptor受体的结合亲和力。针对外围类型的一系列新的高亲和力和选择性配体。

  摘要：

  若干个6-取代或6,8-二取代的2-苯基咪唑并[1,2-α-吡啶-3-羧酸烷基酯5a-h，-乙酸酯5i-s，6a-g和-丙酸酯5t，6h和N，N-二烷基-2-苯基咪唑并[1,2-α吡啶-3-甲酰胺7a-d，-乙酰胺7e-t或-丙酰胺7u是按照新的合成方法制备的，并且它们对两个环的亲和力（CBR ）和外围（PBR）苯并二氮杂receptor受体进行了评估。酯系列化合物对两种受体类型均显示出低亲和力。相反，大多数N，N-二烷基（2-苯基咪唑并[1,2-α吡啶基-3-基]乙酰胺）7e-t对CBR或PBR具有高亲和性和选择性，这取决于C（C 6）-和/或杂环系统上的C（8）。特别是，6-取代的化合物7f-n的IC50值之比（IC50（CBR）/ IC50（PBR））为0.32（7m）至232（7k），而6,8-二取代的化合物7o-t大于PBR的选择性是CBR的1000倍。检查了几种不同的苯二氮卓类

  DOI：

  10.1021/jm970112+
• 作为产物：
  描述：

  6-氯-2-(4-氯苯基)咪唑并[1,2-a]吡啶-3-乙酰胺 生成 6-氯-2-(4-氯苯基)咪唑并[1,2-a]吡啶-3-乙酸
  参考文献：
  名称：

  Imidazo[1,2-a] pyridine derivatives and their application as

  摘要：

  式子：##STR1##中的咪唑并[1,2-a]吡啶及其酸加成盐，其中Y代表氢或卤素原子或C.sub.1-4烷基基团，Z代表萘基团或基团##STR2##其中X.sub.1和X.sub.2各自独立地是氢或卤素原子、C.sub.1-4烷氧基、C.sub.1-6烷基或CF.sub.3、CH.sub.3S--、CH.sub.3SO.sub.2--、--NO.sub.2、--NH.sub.2或--NHCOCH.sub.3，R.sub.1和R.sub.2各自独立地代表氢原子、未取代或取代一个或多个卤素原子或羟基的直链或支链C.sub.1-5烷基、--N(C.sub.1-4烷基).sub.2、氨基甲酰基或C.sub.1-4烷氧基基团、烯丙基、丙炔基、C.sub.3-6环烷基、苄基或苯基，其中R.sub.1和R.sub.2不都是氢，或--NR.sub.1 R.sub.2代表含有3至6个碳原子的杂环或公式##STR3##中的杂环，其中X为O、S、CHOR'或>N--R，R'为氢或苄基，R为氢、C.sub.1-4烷基或苯基，未取代或取代一个甲氧基或卤素原子的苯基，可以从相应的酸制备而成，具有有价值的药理学特性，特别是抗焦虑、抗缺氧、催眠、催眠和抗癫痫特性。

  公开号：

  US04382938A1

文献信息

• Novel L-Dopa and Dopamine Prodrugs Containing a 2-Phenyl-imidazopyridine Moiety
  作者：Nunzio Denora、Valentino Laquintana、Angela Lopedota、Mariangela Serra、Laura Dazzi、Giovanni Biggio、Dhananjay Pal、Ashim K. Mitra、Andrea Latrofa、Giuseppe Trapani、Gaetano Liso

  DOI：10.1007/s11095-007-9255-y

  日期：2007.7

  The aim of this study was to gain insight into the feasibility of enhancing the delivery of L-Dopa and dopamine to the brain by linking these neurotransmitters and L-Dopa ethyl ester to 2-phenyl-3-carboxymethyl-imidazopyridine compounds giving rise to the so-called Dopimid compounds. A number of Dopimid compounds were synthesized and both stability and binding studies to dopaminergic and benzodiazepine receptors were performed. To evaluate whether Dopimid compounds are P-gp substrates, [3H]ritonavir uptake experiments and bi-directional transport studies on confluent MDCKII-MDR1 monolayers were carried out. The brain penetration properties of Dopimid compounds were estimated by the Clark’s computational model and evaluated by investigation of their transport across BBMECs monolayers. The dopamine levels following the intraperitoneal administration of the selected Dopimid compounds were measured in vivo by using brain microdialysis in rat. Tested compounds were adequately stable in solution buffered at pH 7.4 but undergo faster cleavage in dilute rat serum at 37°C. Receptor binding studies showed that Dopimid compounds are essentially devoid of affinity for dopaminergic and benzodiazepine receptors. [3H]ritonavir uptake experiments indicated that selected Dopimid compounds, like L-Dopa and dopamine hydrochloride, are not substrates of P-gp and it was also confirmed by bi-directional transport experiments across MDCKII-MDR1 monolayers. By Clark’s model a significant brain penetration was deduced for L-Dopa ethyl ester and dopamine derivatives. Transport studies involving BBMECs monolayers indicated that some of these compounds should be able to cross the BBB. Interestingly, the rank order of apparent permeability (P app) values observed in these assays parallels that calculated by the computational approach. Brain microdialysis experiments in rat showed that intraperitoneal acute administration of some Dopimid compounds induced a dose-dependent increase in cortical dopamine output. Based on these results, it may be concluded that some Dopimid compounds can be proposed as novel L-Dopa and dopamine prodrugs.

  本研究的目的是探讨通过将这些神经递质和L-Dopa乙酯与2-苯基-3-羧甲基-咪唑并吡啶化合物连接，从而增强L-Dopa和多巴胺向大脑输送的可行性，形成所谓的Dopimid化合物。合成了一些Dopimid化合物，并进行了稳定性和对多巴胺能以及苯二氮卓类受体的结合研究。为了评估Dopimid化合物是否为P-gp底物，进行了[3H]利托那韦摄取实验和在趋同MDCKII-MDR1单层上的双向转运研究。通过Clark的计算模型估算了Dopimid化合物的脑穿透特性，并通过调查其在BBMECs单层上的转运进行了评估。在大鼠体内使用脑微透析测量了选定Dopimid化合物腹腔给药后的多巴胺水平。测试的化合物在pH 7.4的缓冲溶液中稳定性良好，但在37°C的稀释大鼠血清中分解速度较快。受体结合研究表明，Dopimid化合物基本上对多巴胺能和苯二氮卓类受体没有亲和力。[3H]利托那韦摄取实验表明，选定的Dopimid化合物，如L-Dopa和氯化多巴胺，并非P-gp底物，这也通过在MDCKII-MDR1单层上的双向转运实验得到了确认。根据Clark的模型，推断出L-Dopa乙酯和多巴胺衍生物具有显著的脑穿透性。涉及BBMECs单层的转运研究表明，这些化合物中的一些应该能够穿过血脑屏障。有趣的是，在这些实验中观察到的表观渗透性（P app）值的排序与计算方法得出的结果相似。在大鼠的脑微透析实验中，腹腔急性给药某些Dopimid化合物会引起皮层多巴胺输出的剂量依赖性增加。基于这些结果，可以得出结论，某些Dopimid化合物可以被提议作为新型的L-Dopa和多巴胺前药。
• Synthesis of Imidazopyridines from the Morita–Baylis–Hillman Acetates of Nitroalkenes and Convenient Access to Alpidem and Zolpidem
  作者：Divya K. Nair、Shaikh M. Mobin、Irishi N. N. Namboothiri

  DOI：10.1021/ol3020418

  日期：2012.9.7

  have been synthesized through a one-pot, room temperature, and reagent-free reaction between MBH acetates of nitroalkenes and 2-aminopyridines. The reaction involves a cascade inter-intramolecular double aza-Michael addition of 2-aminopyridines to MBH acetates. Our methodology is marked by excellent yield, regioselectivity and, above all, adaptability to synthesize imidazopyridine-based drug molecules

  通过一锅，室温，硝基烯烃的MBH乙酸酯与2-氨基吡啶之间的无试剂反应，已经合成了多种官能化的咪唑并[1,2-a]吡啶。该反应涉及2-氨基吡啶向MBH乙酸酯的级联的分子间双氮杂-Michael加成。我们的方法具有出色的收率，区域选择性以及最重要的是对合成咪唑并吡啶基药物分子（如Alpidem和Zolpidem）的适应性。
• Flow chemistry synthesis of zolpidem, alpidem and other GABA_Aagonists and their biological evaluation through the use of in-line frontal affinity chromatography
  作者：Lucie Guetzoyan、Nikzad Nikbin、Ian R. Baxendale、Steven V. Ley

  DOI：10.1039/c2sc21850j

  日期：——

  The flow of information between chemical and biological research can present a bottleneck in pharmaceutical research. Tools that bridge these disciplines and aid information exchange have therefore clear value. Over the last few years, both synthetic chemistry and biological screening have benefited from automation, and a seamless chemistry–biology interface is now possible. We report here on the use of flow processes to perform synthesis and biological evaluation in an integrated manner. As proof of concept, a flow synthesis of a series of imidazo[1,2-a]pyridines, including zolpidem and alpidem, was developed and connected to a Frontal Affinity Chromatography screening assay to investigate their interaction with Human Serum Albumin (HSA).

  化学研究与生物研究之间的信息流可能成为药物研究的瓶颈。因此，连接这些学科和帮助信息交流的工具具有明显的价值。在过去几年中，合成化学和生物筛选都从自动化中获益匪浅，现在已经可以实现化学与生物学的无缝对接。我们在此报告利用流式工艺综合进行合成和生物评估的情况。作为概念验证，我们开发了一系列咪唑并[1,2-a]吡啶（包括唑吡旦和阿吡旦）的流式合成，并将其连接到额式亲和层析筛选测定，以研究它们与人血清白蛋白（HSA）的相互作用。
• [EN] COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT<br/>[FR] COMPOSITIONS ET MÉTHODES POUR RÉDUIRE UN DYSFONCTIONNEMENT TACTILE, L'ANXIÉTÉ ET UNE DÉFICIENCE SOCIALE
  申请人：HARVARD COLLEGE

  公开号：WO2019232046A1

  公开（公告）日：2019-12-05

  The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome, or for treating touch over-reactivity, pain, or mechanical allodynia.

  本发明涉及一种新型的周围限制非苯二氮平类似物，其具有降低血脑屏障渗透性的特点，以及使用该类似物的方法，用于减少被诊断为自闭症谱系障碍、雷特综合征、费兰基综合征或脆性X综合征的患者的触觉功能障碍、社交障碍和焦虑症状，或用于治疗触摸过度反应、疼痛或机械性痛觉过敏。
• Translocator Protein (TSPO) Ligand−Ara-C (Cytarabine) Conjugates as a Strategy To Deliver Antineoplastic Drugs and To Enhance Drug Clinical Potential
  作者：Nunzio Denora、Valentino Laquintana、Adriana Trapani、Angela Lopedota、Andrea Latrofa、James M. Gallo、Giuseppe Trapani

  DOI：10.1021/mp100235w

  日期：2010.12.6

  The aim of this work was to evaluate TSPO ligand-Ara-C conjugation as an approach for the selective delivery of the antineoplastic agent to brain tumors as well as for overcome P-gp resistance induction observed for the majority of cytotoxic agents, enhancing the drug clinical potential. To this end, the novel N-imidazopyridinacetyl-Ara-C conjugates 3a-c, 10 and 15 have been prepared and evaluated for their cytotoxicity against glioma cell lines. In contrast to that observed for 3a-c and 10, the conjugate 15 resulted stable in both phosphate buffer and physiological medium. In all cases, the release of free Ara-C from hydrolyzed conjugates was checked by HPLC and ESI-MS analysis. Conjugates 10 and 15 displayed very high in vitro TSPO affinity and selectivity, and, hence, they may possess potential for targeted brain delivery. Due to the favorable features displayed by the conjugate 15, it was further evaluated on glioma cell lines, expressing high levels of TSPO, in the presence and in the absence of specific nucleoside transport (NT) inhibitors. In contrast to that observed for the free Ara-C, the presence of NT inhibitors did not reduce the cytotoxic activity of 15. Moreover, conjugate 15, as N-4-acyl derivative of Ara-C, should be resistant to inactivation by cytidine deaminase, and it may possess enhanced propensity to target brain tumor cells characterized by a reduced expression of NTs. In addition, this conjugate behaves as a clear P-gp modulator and thereby may be useful to reverse MDR. Transport studies across the MDCKII-MDR1 monolayer indicated that conjugate 15 should overcome the BBB by transcellular pathway. All these features may be useful for enhancing the clinical potential of the nucleoside drug Ara-C.